TwitterLinkedin

Contact Us

  • Biopharma Excellence
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Current Opportunities
  • Training
Top Bar
Search
PharmaLex Logo
MENUMENU
  • PharmaLex Logo
  • PharmaLex Logo
  • About UsAbout Us
    • About Us
    • Management Team
    • Corporate Social Responsibility
    • What Our Clients Say About Us
  • Our Services
    • Discovery / Non-clinical
          • Go to Discovery / Non-clinical section >>

          • Strategy and Consulting

            • Integrated Product Development
            • Market Access
            • Scientific Advice
            • Statistics and Data Sciences
            • Toxicology Services
    • Clinical Development
          • Go to Clinical Development section >>

          • Strategy and Consulting

            • Clinical Program Development
            • Scientific Advice
            • Statistics and Data Sciences
          • Regulatory Affairs

            • Clinical Trial Applications
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Regulatory Operations
          • Pharmacovigilance

            • Clinical Trial Safety Support
            • Pharmacovigilance Consulting
          • Quality

            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
            • Tech Transfer / Scale-up
    • Authorization / Approval
          • Go to Authorization / Approval section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Regulatory Operations
            • Scientific, Regulatory and Technical Writing
            • Statistics and Data Sciences
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • Pharmacovigilance Consulting
          • Quality

            • Commercialization Readiness
            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • PAI Readiness
    • Post-approval / Maintenance
          • Go to Post-approval / Maintenance section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Mergers and Acquisitions (M&A) Transfers
            • Regulatory Operations
            • Toxicology Services
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • ICSR (Individual Safety Case Report) Management
            • Literature Monitoring & Screening
            • Pharmacovigilance Quality & Compliance
            • Signal Management
          • Quality

            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
          • Medical Affairs

            • Healthcare Compliance and Medical Approval
    • Program Management
          • Go to Program Management section >>

          • Program Management

            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Integrated Product Development
            • Mergers and Acquisitions (M&A) Transfers
    • Featured Expertise
          • Industry Expertise

            • Biopharmaceuticals
            • MedTech Services
          • Service Expertise

            • ATMP / Cell and Gene Therapy
            • COVID-19 Support
            • GxP Services
            • Market Access
            • Pharmacovigilance Consulting
            • Post-Brexit Regulatory Support
            • Statistics and Data Sciences
            • SMARTPHLEX - technology-enabled services
  • Global ReachGlobal Reach
  • Contact usContact us
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Career Opportunities
  • Training
Home > News & Events > Blog > That’s ODD: can your medicine benefit from incentives for treating rare disorders?

That’s ODD: can your medicine benefit from incentives for treating rare disorders?

Author: Vergel Manalo

The time, resources, and costs of developing and marketing medicines are extensive – putting treatments for rare disorders at a distinct disadvantage since the potential return on investment is limited when compared to medicines used for more common conditions. Thus, R&D on treatments for rare diseases was often given a lower priority or abandoned like ‘orphans’ and left patients suffering from the conditions with few options.

Major health authorities have long recognised the need to support organisations to develop interventions for these unmet needs under orphan or rare disease programs. Incentives include:

  • R&D grants;
  • reduced fees for scientific advice;
  • protocol assistance and regulatory activities and licences;
  • market exclusivity; and
  • provisions for accelerating authorisation.

In the US and Europe for instance, when an orphan drug designation (ODD) is granted, a medicine can have market exclusivity for up to 7 years and 10 years, respectively.

In Australia, the incentives are different because of the much smaller population, development and regulatory activities usually occur at a later stage compared to the US and EU, the pricing and reimbursement structures available, and recognition that newer (and better) medicines may be developed. Over the past 20 years or so, the application fees for initial registration (via the TGA) and government reimbursement (via the PBS) for ODD medicines, whether new molecules or established molecules to treat rare conditions, have been waived. At current rates, the total savings for a sponsor in TGA and PBS application fees are close to 0.5 million AUD (new molecule) or 0.3 million AUD (new indication). There is also the prospect that the benefit-risk profile promotes earlier and expedited authorisation.

Although Australian market exclusivity of an ODD medicine is not explicit, another treatment (including one with the same active such as generics) for the same condition/indication will not be designated as an orphan drug by the TGA unless the latter is considered clinically superior or the former is unable to be supplied by its sponsor. Therefore, by their nature market exclusivity for an orphan medicine is usually the case until a better drug becomes available.

What’s the catch?
From 1998 to 2018, the primary criterion for orphan drug designation was that a maximum of 2,000 total individuals in a given year suffered from the disease (or for vaccines and in vivo diagnostics, up to 2,000 individuals eligible to receive the drug per year). This led to a practice colloquially called ‘salami slicing’ – where sponsors would propose a specific therapeutic indication that would limit the prevalence to under 2,000 to qualify for orphan status, despite other patients with the disease being excluded by certain criteria such as age, sex, genetic characteristics, disease variants, diagnostic criteria or prior treatments.

In August 2018, the TGA revised their ODD eligibility criteria to avoid such manipulations as a trade-off for increasing the prevalence to 5 in 10,000 individuals (roughly 12,500 patients at Australia’s current population of about 25 million). Other criteria have been introduced which must all be met if the drug is to be designated as an orphan TGA Orphan Drug Designation Eligibility Criteria:

  1. The condition is life-threatening or seriously debilitating.
  2. Only one indication for the drug to be orphan designated – which may differ to the proposed therapeutic indication where inclusion/exclusion criteria are often introduced based on the clinical studies available to date.
  3. The medical plausibility of the drug being used in another patient class other than that specified by the indication has been considered and ruled out (as the treatment population could potentially exceed the prevalence threshold).
  4. Although the threshold for prevalence of the disease is capped at 5 in 10,000, an exception can be made if financially viability is positively influenced by waiving the application fee for registration.
  5. Prevalence is the estimated total number of patients afflicted – which takes into account epidemiological data such as baseline numbers, rates at which new patients are diagnosed per year (incidence) and patients no longer affected (from successful treatment of signs and symptoms, and mortality). Where Australian data are limited, overseas data and/or literature are allowed with a justification or explanation on its applicability to the local population.
  6. Market authorisation has not been refused on safety grounds by the US FDA, EMA, MHRA or Health Canada.
  7. Either, no other medicine is registered on the Australian Register of Therapeutic Goods (ARTG) for the condition or the drug provides significant benefit over existing treatments for the condition.

Since a big part of the incentives is a waiver for the TGA and PBS application fees, an application for orphan drug designation by the TGA should be made before making a submission for a market authorisation (MA) for the drug in Australia. It is expected that the MA application is submitted within 6- months of the orphan drug designation being granted, otherwise, eligibility may be extended or revoked based on updated data. The application for PBS reimbursement should be made concurrently or within 12- months from registration on the ARTG.

If you are considering an opportunity for your drug to be authorised in Australia and think that it qualifies for the incentives as an ODD medicine, please reach out to Brandwood CKC for assistance or further information.

Contact us
Related posts
Sponsors gear up for a smoother process with CTIS but must first overcome key hurdles
Sponsors gear up for a smoother process with CTIS but must first overcome key hurdles
2nd June 2022
Medical device software brings new complications around compliance
Medical device software brings new complications around compliance
30th May 2022
Is quality documentation an asset or a burden in regulatory affairs?
Is quality documentation an asset or a burden in regulatory affairs?
6th April 2022
Navigating the impact of the IVDR on marketed products
Navigating the impact of the IVDR on marketed products
24th March 2022
Minimizing risk during the transport of medicinal products
Minimizing risk during the transport of medicinal products
21st March 2022
Next Steps for EUDAMED implementation within MDR
Next Steps for EUDAMED implementation within MDR
7th March 2022
Recent Blogs
  • Sponsors gear up for a smoother process with CTIS but must first overcome key hurdles
    2nd June 2022
  • Medical device software brings new complications around compliance
    30th May 2022
  • Is quality documentation an asset or a burden in regulatory affairs?
    6th April 2022
  • Navigating the impact of the IVDR on marketed products
    24th March 2022
  • Minimizing risk during the transport of medicinal products
    21st March 2022
  • Next Steps for EUDAMED implementation within MDR
    7th March 2022
Recent News
  • Why collaboration and an Integrated Product Development program are key to successful drug development
    14th June 2022
  • Key Takeaways from the PDA Europe Annex 1 Workshop
    7th June 2022
  • Addressing Limitations of Sterility Testing
    9th May 2022
  • Are virtual audits sustainable post-pandemic?
    6th May 2022
  • Orphan Drug Designation: Securing the Significant Benefits
    28th March 2022
  • PharmaLex expands pricing & reimbursement and health economics platform with EBMA Consulting merger
    9th March 2022
Upcoming Webinars

July 28th, 2022

The regulatory and business importance of medical device post-market surveillance

09:00 AM CET

Biopharma Excellence Website Image

PharmaLex Brings You Biopharma Excellence

Biopharma Excellence is a fusion of three scientific powerhouses, PharmaLex, ERA Consulting and Biopharma Excellence – all under the PharmaLex brand. This global team of scientific, regulatory and commercial professionals provide strategic product development and proactive regulatory services to developers of biopharmaceuticals, cell and gene therapies, monoclonal antibodies (MABs), vaccines and biosimilars.

Visit Website
USEFUL LINKS
  • Home
  • Contact us
  • Imprint
  • Data Protection
  • Terms and Conditions
RECENT TWEETS
PharmaLexGLOBALPharmaLex@PharmaLexGLOBAL·
30 Jun

The #CTIS brings many opportunities, but it will also require a lot of process changes and preparation, find out more 👉https://lnkd.in/eZRqyPPX about the benefits and challenges with the CTIS.

➡  Take the @Phlexglobal #survey! https://lnkd.in/eA5FwHJC

COVID-19 NEWSLETTER SIGN UP

SIGN UP NOW

WHAT OUR CLIENTS SAY
  • PharmaLex is dedicated to delivering a comprehensive portfolio while their modular approach allows tailor-made solutions. They acknowledge our feedback, modify their approach and adapt accordingly.

    Top 10 Pharma Company
    President
PharmaLex
©2022 PharmaLex GmbH. All rights reserved.

ISO9001:2015 LogoEnergie Audit LogoSGS Logo

Suspicious Emails

We are aware of a number of suspicious emails about recruitment in circulation purporting to be from PharmaLex. Emails sent by PharmaLex will originate from @pharmalex.com. Should you receive an email and are unsure as to its validity, please report it to contact@pharmalex.com.

Many thanks for your understanding.

The PharmaLex Team

    Please DO NOT send us event/conference information.
    We will not respond and these will be deleted immediately.






    Select your state:

    .
    If you do not wish to receive any communication from us, you may unsubscribe at any time.

    #AskTheExpert #TogetherBEYONDCOVID19





      Select your state:

      .
      You can unsubscribe at any time at data.protection@pharmalex.com

      If you do not wish to receive any communication from us, you can unsubscribe at any time at. Click here to view our Privacy Policy.

      #TogetherBEYONDCOVID19

      We closely monitor developments and updates surrounding the current outbreak of Coronavirus Disease 2019 (COVID-19) from official sources including the World Health Organisation and are following the guidance and direction of the governments and the local authorities. We are taking this situation very seriously and our number one priority is the safety and business continuity for our customers and colleagues. As ever, we will do everything we can to ensure that services are delivered within the required time and the trusted quality PharmaLex is known for